Best Life Sciences Companies in Rhode Island, United States
The 49 best Life Sciences companies in Rhode Island, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nabsys.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Rhode Island
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nabsys Developer of tools to map whole genome sequencing | $145M | 45 mo ago | 44 44 → 88 (+100%) | Barrett Bready Founder & CEO | WebflowHubSpotSalesforce Marketing Cloud Account Engagement+20 | Top 10M | 70 patents High-resolution single-molecule DNA mapping and analysis for genomic and biomolecular diagnostics. | 1 job opening · 2 partnerships · 1 award |
| 2 | IlluminOss Medical Orthopedic implants | $62M | 126 mo ago | 21 21 → 32 (+52%) | Robert Rabiner Chief Technical Officer / Founder | Node.jsReactNext.js+9 | Top 50M | 240 patents Advanced orthopedic bone fixation devices and photodynamic joint implants | — |
| 3 | Neurotech Developer of a cell-based delivery device for the treatment of eye diseases | $53M | 213 mo ago | 48 | Rich Small Chief Executive Officer | WordPress Block EditorWebflowWordPress+20 | Top 5M | — | 1 job opening |
| 4 | Tivorsan Speciality pharma company that develops novel treatment for life threatening neuromuscular disorders | $16M | 96 mo ago | 6 | Joel Braunstein Co-Founder | — | — | — | — |
| 5 | Edesia A foundation focused on the health crisis | $12M | 198 mo ago | 116 116 → 100 (-14%) | — | WordPressMySQLPHP+30 | Top 5M | — | — |
| 6 | Mnemosyne Pharmaceuticals Developer of small molecule therapeutics for neuropsychiatric conditions | $11M | 157 mo ago | 4 | Kollol Pal CEO | — | — | — | — |
| 7 | pHLIP Targeted therapeutics delivery platform for acidic diseased tissues, improving patient outcomes | $8M | 93 mo ago | — | Donald Engelman Co-Founder | — | — | 13 patents pH-sensitive peptide carriers for targeted radiolabeled imaging and intracellular nucleic acid delivery | — |
| 8 | Isis Biopolymer Transdermal drug delivery systems | $8M | 197 mo ago | 37 | Chris Hobson President & CEO | — | — | 24 patents Transdermal iontophoretic drug delivery patches and devices for targeted skin application. | — |
| 9 | Premama Wellness Powdered supplements to support postnatal nutritional needs | $7M | 75 mo ago | 2 | William Do Co-Founder | Cart FunctionalityShopifySentry+41 | Top 10M | 3 patents Test strip holders for point‑of‑care diagnostic assay devices | — |
| 10 | InCytu Immunotherapies to treat cancer | $5M | 174 mo ago | — | Alfred Vasconcellos President and CEO | — | — | 7 patents Targeted immunotherapy vaccines and antigen delivery systems for therapeutic immune activation | — |
| 11 | CNine Provider of an in-vitro diagnostic tool for meningitis | $2M | 93 mo ago | — | Scott Barnum Co-Founder & CSO | — | — | — | — |
| 12 | MultiCell Technologies Developer of therapeutics for neurological disorders, hepatic disease, and cancer | $1M | 175 mo ago | 2 | Jerry Newmin Chairman & CEO | — | — | 15 patents Immortalized hepatocyte cell lines for therapeutic protein manufacturing | — |
| 13 | Kiffik Provider of wearable device to monitor body biomarkers | $830K | 7 mo ago | 15 | George Cagna President and Chief Executive Officer | WordPress Block EditorElementorWordPress+32 | Top 50M | — | — |
| 14 | EpiVax Immunoinformatics modeling and gene sequencing for vaccines and drugs | $795K | 18 mo ago | 43 | Anne Groot Founder & CEO | WordPressApple iCloud MailMicrosoft 365+28 | Top 5M | 184 patents Designing T‑cell epitope vaccines and immunotherapies for viral diseases | 1 expansion |
| 15 | ProThera Biologics Pioneering therapies restoring immune regulation to fight severe inflammatory diseases | $750K | 15 mo ago | 5 | — | — | — | 53 patents Quantitative assays, purification, and therapeutic use of inter‑alpha inhibitor proteins for lung disease. | — |
| 16 | Calista Therapeutics Developer of CAL inhibitor for the treatment of cystic fibrosis | $675K | 145 mo ago | 7 | — | — | — | — | — |
| 17 | 121nexus Cloud-based track and trace solutions for medical device manufacturers | $500K | 151 mo ago | — | Albert Ho Co-Founder | — | — | — | — |
| 18 | CytoSolv Biotech company developing encapsulating cell technology for indications in cell therapy; acquired by Semma… | $500K | 163 mo ago | 8 | — | — | — | — | — |
| 19 | Epivax Oncology Developer of mutanome-directed, neo-epitope therapeutic vaccines | $375K | 82 mo ago | 2 | Annie De Groot CEO & Director | — | — | 5 patents Design and formulation of neo‑epitope peptide cancer vaccines for personalized immunotherapy | — |
| 20 | Medley Genomics Working towards assessing the complex genomic heterogeneity in biological samples | $250K | 115 mo ago | 4 | — | — | — | — | — |
| 21 | Empath Labs Developer of patient engagement programs and social-emotional learning companions | $149K | 136 mo ago | 10 | Joel Schwartz Founder & CTO | — | — | 6 patents AI-based skill inference platforms using data stores and machine learning models. | — |
Top 12 Life Sciences companies in Rhode Island
#1
Series A · Providence, Rhode Island · founded 2019 · 15 employees$830Kraised▾
Provider of wearable device to monitor body biomarkers. The company offers a non-invasive, wearable, device to access interstitial fluid (ISF) for monitoring an individual’s biomarkers.
- Dec 2025Series A—
- Jun 2022Seed$830K
#2
Series A · East Providence, Rhode Island · founded 2001 · 5 employees$750Kraised▾
Pioneering therapies restoring immune regulation to fight severe inflammatory diseases. This company is developing a new approach to treating severe inflammation by modulating multiple pathways to restore patient health. They focus on human plasma proteins, specifically Inter-alpha inhibitor proteins (IAIP), naturally-occurring anti-inflammatory proteins, to treat patients with severe inflammatory diseases. Their goal is to create a first-in-class, life-saving medicine to stop and reverse the course of inflammatory diseases. This is a B2B model focused on therapeutic areas and scientific advancements in healthcare.
- Apr 2025Grant (prize money)$4.4M
- Jan 2019Series A$750K
- Jan 2018Conventional Debt$250K
- Aug 2014Grant (prize money)$498.1K
#3
Acquired · Providence, Rhode Island · founded 2004 · 44 employees$145Mraised▾
Nabsys focuses on mapping the whole genome and for that purpose, has developed a solid-state nano detectors technology for the analysis of long DNA molecules at high velocity. The platform works by identifying the location of sequence-specific tags added to the long DNA, and this information is further analyzed, validated, and characterized by a suite of software tools from the company.
- Nov 2022Series E$13M
- Apr 2022Series E$25M
- Oct 2019Series D$21M
- Aug 2014Series D$25.5M
#4
Acquired · Providence, Rhode Island · founded 1998 · 43 employees$794.9Kraised▾
Immunoinformatics modeling and gene sequencing for vaccines and drugs. The company offers a T cell epitope-driven vaccine for covid-19, a biodefense vaccine for smallpox, tularemia, TB, pylori, and influenza, The vaccines are developed by editing protein sequences using proprietary immuno-informatics tool called tregitope and de-immunization.
- Feb 2025Grant (prize money)$5.5M
- Sep 2023Grant (prize money)$299.9K
- Aug 2023Grant (prize money)$299.9K
- Sep 2022Grant (prize money)$2M
#5
Seed · South Kingstown, Rhode Island · founded 2011$92.5Kraised▾
Developer of a medical device for brain monitoring brain for disorder diagnosis and treatment. The company's brain monitoring device "tEEG", uses the Tripolar Concentric Ring Electrodes (TCREs), to detect signals on the scalp’s surface. The tEEG system provides artifact suppression. High-frequency oscillations (HFOs) are considered the biomarkers for early seizure development and epileptogenic zone. The device offers a non-invasive method to detect HFOs from the scalp which can potentially help to predict when a person may have a seizure like those associated with epilepsy.
- Mar 2025Grant (prize money)$2.5M
- May 2019Grant (prize money)$150K
- May 2017Seed$92.5K
- Dec 2014Grant (prize money)$179.9K
#6
Acquired · East Providence, Rhode Island · founded 2007 · 21 employees$62.5Mraised▾
IlluminOss Medical is a privately held medical device company focused on minimally invasive orthopedic systems for the stabilization and treatment of bone fractures. The IlluminOss Photodynamic Bone Stabilization System utilizes a photodynamic (light-curable) polymer system designed to eliminate the need for traditional methods of bone fixation with external pins, plates and screws. Product is available outside the US.
- Jan 2016Series C$5M
- Jun 2014Series C$6.5M
- Oct 2012Series C$28M
- Jun 2012Series B$1M
#7
Series B · Cumberland, Rhode Island · founded 2000 · 48 employees$53.3Mraised▾
Developer of a cell-based delivery device for the treatment of eye diseases. The company is developing an innovative delivery platform for the treatment of retinal-based diseases. The company's flagship product is an implantable device containing genetically-modified cells that release protein-based therapeutics for the treatment of Macular Telangiectasia (MacTel) and other retinal diseases.
- Oct 2008Series B$4M
- Nov 2006Series B$35M
- Nov 2003Series A$14.3M
#8
Deadpooled · Providence, Rhode Island · founded 2008 · 6 employees$15.6Mraised▾
Tivorsan Pharmaceuticals is focused on developing novel treatment approaches to address all forms of Duchenne Muscular Dystrophy (DMD) and Becker’s Muscular Dystrophy (BMD), as well as other progressive, life threatening neuromuscular disorders. lead candidate therapeutic, recombinant human Biglycan has a unique Mechanism of Action (MOA): up-regulating utrophin, nNOS and other dystrophin-associated proteins at the muscle membrane. This unique and differentiated MOA provides a strong platform to develop a series of first or best in class therapies for a range of neuromuscular disorders beyond DMD and BMD, including Congenital Muscular Dystrophy, ALS, Spinal Muscular Atrophy and Myasthenia Gravis. Company expects to initiate clinical trial phase 1 in early 2017
- Jul 2018Series A$900K
- Mar 2017Series A$4.5M
- Feb 2016Series A$1.8M
- Jan 2016Series A$2.9M
#9
Series B · Providence, Rhode Island · founded 2011 · 2 employees$7.4Mraised▾
Premama Wellness has made natural powdered supplements formulated to support preconception through postnatal nutritional needs, concerns, and conditions. Premama’s pill-free, drink mix solutions contain clinically-studied and physician approved ingredients and are designed to blend with liquids and soft foods.
- Apr 2020Series B—
- Dec 2019Series B$2.3M
- Mar 2018Conventional Debt$210K
- Mar 2018Series B$516.8K
#10
Series A · Providence, Rhode Island · founded 2010 · 4 employees$11.4Mraised▾
Developer of small molecule therapeutics for neuropsychiatric conditions. The company is focused on targeting the NMDA receptor, which is known to be the "master" switch for learning and memory. The company's two lead programs target schizophrenia and Rett Syndrome.
- Jun 2013Series A$6M
- Feb 2012Series A$5.4M
#11
Series A · South Kingstown, Rhode Island · founded 2015$7.9Mraised▾
Targeted therapeutics delivery platform for acidic diseased tissues, improving patient outcomes. This is a biotechnology company focused on developing and utilizing its proprietary peptide-based platform technology to selectively deliver therapeutic and imaging agents to acidic cells in diseased tissues. The technology targets a metabolic feature of activated stromal, myeloid, and cancer cells: their high cell surface acidity. This targeted approach aims to improve therapeutic efficacy and reduce side effects in treating cancer, inflammation, and other acidic tissue diseases. The platform enables marking acidic cells for surgical removal, activating an immune response, reprogramming acidic cells, or killing acidic cells. This innovative approach has the potential to enable cures and save lives.
- Oct 2018Series A$4.4M
- Sep 2017Series A$3.4M
#12
Funding Raised · North Kingstown, Rhode Island · founded 2010 · 116 employees$11.8Mraised▾
A foundation focused on the health crisis. The company focuses on developing ready-to-use foods to help the global hunger and malnutrition crisis. The company's products inlcude Plumpy nut, Plumpy sup, Plumpy doz, and Enov nutributter.
- Jan 2010Grant (prize money)$11.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.